MXPA03007908A - Una formulacion farmaceutica estable que comprende una modificacion de torsemida ii. - Google Patents
Una formulacion farmaceutica estable que comprende una modificacion de torsemida ii.Info
- Publication number
- MXPA03007908A MXPA03007908A MXPA03007908A MXPA03007908A MXPA03007908A MX PA03007908 A MXPA03007908 A MX PA03007908A MX PA03007908 A MXPA03007908 A MX PA03007908A MX PA03007908 A MXPA03007908 A MX PA03007908A MX PA03007908 A MXPA03007908 A MX PA03007908A
- Authority
- MX
- Mexico
- Prior art keywords
- modification
- torsemide
- high purity
- pharmaceutical formulation
- stable pharmaceutical
- Prior art date
Links
- NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 title claims abstract description 181
- 229960005461 torasemide Drugs 0.000 title claims abstract description 180
- 238000012986 modification Methods 0.000 title claims abstract description 157
- 230000004048 modification Effects 0.000 title claims abstract description 157
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 47
- 238000000034 method Methods 0.000 claims abstract description 27
- 239000000203 mixture Substances 0.000 claims abstract description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 238000009472 formulation Methods 0.000 claims abstract description 8
- 238000004090 dissolution Methods 0.000 claims description 24
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 22
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 15
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 14
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 14
- 238000009826 distribution Methods 0.000 claims description 9
- 239000002245 particle Substances 0.000 claims description 9
- 229940069328 povidone Drugs 0.000 claims description 9
- 229960000913 crospovidone Drugs 0.000 claims description 8
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 8
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 8
- 238000000338 in vitro Methods 0.000 claims description 6
- 206010030113 Oedema Diseases 0.000 claims description 5
- 235000019359 magnesium stearate Nutrition 0.000 claims description 5
- 229960004977 anhydrous lactose Drugs 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 2
- 235000010980 cellulose Nutrition 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 12
- 238000000634 powder X-ray diffraction Methods 0.000 description 25
- 238000003860 storage Methods 0.000 description 16
- 239000004480 active ingredient Substances 0.000 description 9
- 239000000546 pharmaceutical excipient Substances 0.000 description 9
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 7
- 239000008108 microcrystalline cellulose Substances 0.000 description 7
- 239000013078 crystal Substances 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000008213 purified water Substances 0.000 description 3
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 239000011149 active material Substances 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000002050 diffraction method Methods 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 238000007922 dissolution test Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 239000008190 ground granulate Substances 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000000371 solid-state nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000007916 tablet composition Substances 0.000 description 2
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229940066468 demadex Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000002171 loop diuretic Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18328800P | 2000-02-17 | 2000-02-17 | |
| PCT/US2001/005577 WO2002067935A1 (en) | 2000-02-17 | 2001-02-21 | A stable pharmaceutical formulation comprising torsemide modification ii |
| US09/789,424 US6482417B2 (en) | 2000-02-17 | 2001-02-21 | Stable pharmaceutical formulation comprising torsemide modification II |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA03007908A true MXPA03007908A (es) | 2004-12-06 |
Family
ID=27359046
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA03007908A MXPA03007908A (es) | 2000-02-17 | 2001-02-21 | Una formulacion farmaceutica estable que comprende una modificacion de torsemida ii. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US6482417B2 (enExample) |
| EP (1) | EP1292303B1 (enExample) |
| JP (1) | JP2004522780A (enExample) |
| CN (1) | CN1505512A (enExample) |
| AT (1) | ATE266404T1 (enExample) |
| CA (1) | CA2410802A1 (enExample) |
| DE (2) | DE1292303T1 (enExample) |
| DK (1) | DK1292303T3 (enExample) |
| ES (1) | ES2193007T3 (enExample) |
| HR (1) | HRP20030762A2 (enExample) |
| HU (1) | HUP0600143A2 (enExample) |
| IL (1) | IL157539A0 (enExample) |
| IS (1) | IS6919A (enExample) |
| MX (1) | MXPA03007908A (enExample) |
| NO (1) | NO20033699L (enExample) |
| PT (1) | PT1292303E (enExample) |
| SI (1) | SI1292303T1 (enExample) |
| SK (1) | SK11632003A3 (enExample) |
| TR (1) | TR200401462T4 (enExample) |
| WO (1) | WO2002067935A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10013289A1 (de) * | 2000-03-17 | 2001-09-20 | Knoll Ag | Torasemid enthaltende pharmazeutische Zubereitungen |
| US20030022921A1 (en) * | 2001-02-21 | 2003-01-30 | Minutza Leibovici | Stable pharmaceutical formulation comprising torsemide modification II |
| ITMI20020639A1 (it) * | 2002-03-27 | 2003-09-29 | Cosma S P A | Composizioni farmaceutiche comprendenti come principio attivo 1-isopropil-3°(4-m-toluidino-3-pridil)sulfonil!-urea |
| WO2005044187A2 (en) * | 2003-10-28 | 2005-05-19 | Glaxo Group Limited | Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same |
| ES2244324B1 (es) * | 2004-03-25 | 2006-11-16 | Ferrer Internacional, S.A. | Composiciones diureticas de liberacion prolongada. |
| CN100421662C (zh) * | 2005-11-08 | 2008-10-01 | 周卓和 | 托拉塞米分散片及其制备方法和应用 |
| CN100372534C (zh) * | 2006-04-20 | 2008-03-05 | 南京海辰药业有限公司 | 托拉塞米冻干制剂及制备方法 |
| US20080213362A1 (en) * | 2007-02-02 | 2008-09-04 | Lawrence Solomon | Compositions and methods using torsemide |
| CN106038500A (zh) * | 2016-05-26 | 2016-10-26 | 南京正科医药股份有限公司 | 一种托拉塞米片 |
| KR20240052937A (ko) * | 2021-07-20 | 2024-04-23 | 미네랄리스 테라퓨틱스, 아이엔씨. | 이치환된 1, 2, 4-트리아진 화합물의 염을 포함하는 가용성 약제학적 조성물 |
| GR1010905B (el) * | 2024-04-15 | 2025-03-10 | Win Medica Φαρμακευτικη Ανωνυμη Εταιρεια, | Δισκιο που περιεχει τορασεμιδη |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1477664A (en) | 1974-04-17 | 1977-06-22 | Christiaens Sa A | Pyridine derivatives |
| DE3529529A1 (de) | 1985-08-17 | 1987-02-19 | Boehringer Mannheim Gmbh | Verfahren zur herstellung einer stabilen modifikation von torasemid |
| DE69624559T2 (de) * | 1995-02-28 | 2003-07-10 | Aventis Pharmaceuticals Inc., Bridgewater | Arzneizubereitungen für piperidinalkanolderivate |
| US5914336A (en) * | 1998-06-02 | 1999-06-22 | Boehringer Mannheim Gmbh | Method of controlling the serum solubility of orally administered torasemide and composition relating thereto |
| KR20020025217A (ko) * | 1999-08-11 | 2002-04-03 | 추후보정 | 토르세미드 동질이상 |
-
2001
- 2001-02-21 ES ES01911078T patent/ES2193007T3/es not_active Expired - Lifetime
- 2001-02-21 AT AT01911078T patent/ATE266404T1/de not_active IP Right Cessation
- 2001-02-21 SK SK1163-2003A patent/SK11632003A3/sk not_active Application Discontinuation
- 2001-02-21 CN CNA018231683A patent/CN1505512A/zh active Pending
- 2001-02-21 TR TR2004/01462T patent/TR200401462T4/xx unknown
- 2001-02-21 DE DE1292303T patent/DE1292303T1/de active Pending
- 2001-02-21 MX MXPA03007908A patent/MXPA03007908A/es not_active Application Discontinuation
- 2001-02-21 WO PCT/US2001/005577 patent/WO2002067935A1/en not_active Ceased
- 2001-02-21 HR HR20030762A patent/HRP20030762A2/xx not_active Application Discontinuation
- 2001-02-21 JP JP2002567302A patent/JP2004522780A/ja not_active Withdrawn
- 2001-02-21 HU HU0600143A patent/HUP0600143A2/hu unknown
- 2001-02-21 EP EP01911078A patent/EP1292303B1/en not_active Revoked
- 2001-02-21 SI SI200130132T patent/SI1292303T1/xx unknown
- 2001-02-21 DE DE60103276T patent/DE60103276T2/de not_active Expired - Fee Related
- 2001-02-21 DK DK01911078T patent/DK1292303T3/da active
- 2001-02-21 US US09/789,424 patent/US6482417B2/en not_active Expired - Fee Related
- 2001-02-21 CA CA002410802A patent/CA2410802A1/en not_active Abandoned
- 2001-02-21 IL IL15753901A patent/IL157539A0/xx unknown
- 2001-02-21 PT PT01911078T patent/PT1292303E/pt unknown
-
2003
- 2003-08-20 IS IS6919A patent/IS6919A/is unknown
- 2003-08-20 NO NO20033699A patent/NO20033699L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| SK11632003A3 (sk) | 2004-04-06 |
| DE1292303T1 (de) | 2003-09-18 |
| JP2004522780A (ja) | 2004-07-29 |
| NO20033699D0 (no) | 2003-08-20 |
| PT1292303E (pt) | 2004-09-30 |
| IS6919A (is) | 2003-08-20 |
| IL157539A0 (en) | 2004-03-28 |
| ES2193007T1 (es) | 2003-11-01 |
| CA2410802A1 (en) | 2002-09-06 |
| HRP20030762A2 (en) | 2005-08-31 |
| WO2002067935A1 (en) | 2002-09-06 |
| SI1292303T1 (en) | 2004-10-31 |
| HUP0600143A2 (en) | 2006-10-28 |
| ATE266404T1 (de) | 2004-05-15 |
| US20020035135A1 (en) | 2002-03-21 |
| EP1292303A1 (en) | 2003-03-19 |
| DE60103276T2 (de) | 2005-06-23 |
| NO20033699L (no) | 2003-10-10 |
| EP1292303A4 (en) | 2003-07-09 |
| DK1292303T3 (da) | 2004-09-06 |
| DE60103276D1 (de) | 2004-06-17 |
| US6482417B2 (en) | 2002-11-19 |
| CN1505512A (zh) | 2004-06-16 |
| ES2193007T3 (es) | 2004-11-01 |
| EP1292303B1 (en) | 2004-05-12 |
| TR200401462T4 (tr) | 2004-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4295988B2 (ja) | 医薬形態のアトルバスタチンカルシウム、その構成物、及びアトルバスタチンカルシウムを含む医薬製剤 | |
| RS57561B1 (sr) | Formulacija dobijena direktnom kompresijom i proces za njeno dobijanje | |
| US10653626B2 (en) | Powder for oral suspension containing lamotrigine | |
| US20090324718A1 (en) | Imatinib compositions | |
| EP1292303B1 (en) | A stable pharmaceutical formulation comprising torsemide modification ii | |
| JPS638332A (ja) | 医薬組成物 | |
| US4666919A (en) | Stabilized pharmaceutical composition containing an isocarbostyril derivative | |
| JP6957807B2 (ja) | 右旋性オキシラセタムの２型結晶、調製方法および用途 | |
| SK283249B6 (sk) | Tableta vyrobiteľná priamym tabletovaním, obsahujúca aktívnu látku kyselinu 4-amino-1-hydroxybutylidén-1,1-bisfosfónovú a spôsob jej výroby | |
| EP2067470A1 (en) | Pharmaceutical compositions containing valsartan and process for its preparation | |
| EP3470062B1 (en) | Pharmaceutical tablet composition comprising bilastine polymorphic form 3 and magnesium aluminometasilicate | |
| JP7704830B2 (ja) | シタグリプチン及びダパグリフロジンを含む複合製剤、及びその製造方法 | |
| RU2188018C2 (ru) | Композиционный состав антибактериального лекарственного средства | |
| US20030022921A1 (en) | Stable pharmaceutical formulation comprising torsemide modification II | |
| AU2001238617A1 (en) | A stable pharmaceutical formulation comprising torsemide modification II | |
| ZA200306679B (en) | A stable pharmaceutical formulation comprising torsemide modification II. | |
| KR20030077638A (ko) | 토르세마이드 변형체 ⅱ를 포함하는 안정한 약학 제제 | |
| CZ20032513A3 (cs) | Stabilní farmaceutický přípravek obsahující modifikaci II torsemidu | |
| US20030065035A1 (en) | Novel stilbene derivative crystal and method for producing the same | |
| KR20190007370A (ko) | 바제독시펜 또는 그의 약제학적으로 허용가능한 염, 및 콜레칼시페롤 또는 그의 약제학적으로 허용가능한 염을 포함하는 우수한 안정성 및 용출률을 갖는 복합제제 | |
| CN119060046A (zh) | 含有格拉匹纶盐酸盐的药物制剂及其制备方法 | |
| KR20190047239A (ko) | 바제독시펜 또는 그의 약제학적으로 허용가능한 염 및 콜레칼시페롤 또는 그의 약제학적으로 허용가능한 염을 포함하는, 습식과립법을 이용하여 제조되는 복합제제 | |
| KR950007229B1 (ko) | 케토티펜을 함유한 약학적 조성물 | |
| KR20200002409A (ko) | 폴라프레징크를 포함하는 습식과립 조성물 및 이를 이용한 정제의 제조 방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |